MDS Nordion, Guerbet to develop PET agents

Jun 23, 2010

MDS Nordion of Ottawa has entered into a collaboration to develop new PET radiotracers for cancer diagnostics.

MDS Nordion will work with French contrast developer Guerbet, of Roissy, and Cyceron, a biomedical imaging center in France, to investigate a radiopharmaceutical based on gallium-68 (Ga-68), assessing its functionality, image quality, and commercial feasibility, according to MDS Nordion.

Under the terms of the agreement, MDS Nordion, Guerbet, and Cyceron will provide complementary expertise in radiochemistry, radiolabeling, and targeted delivery of radioisotopes. Guerbet will lead the project for its duration as the scientific coordinator. In addition, each party will provide scientific resources and in-kind contributions to the project, MDS Nordion said.

MDS inks deals to sell Pharma Services units, February 12, 2010

MDS names Anderson as chairman, February 2, 2010

MDS to lay off 150 in Toronto, February 1, 2010

MDS blames isotope shortage for poor Q4, January 22, 2010

$ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.$